Vestcor Inc Lowers Position in Medpace Holdings, Inc. (NASDAQ:MEDP)

Vestcor Inc trimmed its position in Medpace Holdings, Inc. (NASDAQ:MEDP) by 12.5% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 4,507 shares of the company’s stock after selling 645 shares during the period. Vestcor Inc’s holdings in Medpace were worth $1,497,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in the company. GSA Capital Partners LLP bought a new stake in shares of Medpace in the 3rd quarter worth approximately $276,000. KBC Group NV increased its stake in Medpace by 5.5% during the 3rd quarter. KBC Group NV now owns 1,213 shares of the company’s stock valued at $405,000 after purchasing an additional 63 shares in the last quarter. Natixis Advisors LLC purchased a new position in Medpace in the third quarter worth about $3,754,000. Mutual of America Capital Management LLC lifted its stake in shares of Medpace by 1.9% in the third quarter. Mutual of America Capital Management LLC now owns 13,738 shares of the company’s stock worth $4,586,000 after buying an additional 255 shares in the last quarter. Finally, Thrivent Financial for Lutherans grew its holdings in shares of Medpace by 61.3% during the third quarter. Thrivent Financial for Lutherans now owns 14,430 shares of the company’s stock valued at $4,817,000 after buying an additional 5,484 shares during the last quarter. Institutional investors own 77.98% of the company’s stock.

Medpace Trading Up 2.2 %

Shares of MEDP opened at $324.95 on Friday. The firm has a fifty day simple moving average of $340.28 and a two-hundred day simple moving average of $341.12. The firm has a market cap of $9.90 billion, a PE ratio of 25.73, a P/E/G ratio of 3.81 and a beta of 1.47. Medpace Holdings, Inc. has a 1-year low of $302.01 and a 1-year high of $459.77.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. As a group, research analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Robert W. Baird boosted their price objective on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Hold” and an average target price of $381.44.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.